clinical trial · NCT07441278
A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NS Pharma, Inc.·phase2·not yet recruiting·n = 177
Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NS-863 Low DoseNS-863 High DosePlacebo
brief summary
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
started
Jul 1, 2026
primary completion
Sep 14, 2028
completion
Dec 14, 2028
last updated
Feb 27, 2026
official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol